Abstract
A desirable characteristic of a drug is linear pharmacokinetic properties to facilitate dose and dose regimen adjustment in patients. “Linear pharmacokinetics” implies that any concentration–time profiles normalized for dose and time are superimposable (Ludden 1991). Thus, one of the necessary conditions for linear pharmacokinetics is dose proportionality, and its assessment is a fundamental pharmacokinetic analysis conducted during the clinical development of a new drug candidate.
This is a preview of subscription content, log in via an institution to check access.
References and Further Reading
Cawello W, Brett M, Weimann H-J, Zimmerman H, Pabst G, Sierakowski B, Gieschke R, Baumann A (1999) Parameters for compartment-free pharmacokinetics: standardisation of study design, data analysis, and reporting. Shaker Verlag, Aachen
EMEA CPMP (2010) Guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr)
EMEA CPMP (2014) Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1)
Frick A, Marshallsay C, Steinstraesser WR (2006) Clinical studies – typical designs. In: Vogel HG, Maas J, Mayer D, Hock F (eds) Drug discovery and evaluation: safety and pharmacokinetic assays. Springer, Berlin/Heidelberg
Gough K, Hutchison M, Keene O, Byrom B, Ellis S, Lacey L, McKellar J (1995) Assessment of dose proportionality: report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party. Ther Innov Regul Sci 29(3):1039–1048
Hummel J, McKendrick S, Brindley C, French R (2009) Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat 8:38–49. https://doi.org/10.1002/pst.326
Ludden TM (1991) Nonlinear pharmacokinetics: clinical implications. Clin Pharmacokinet 20:429–446
Sethuraman VS, Leonov S, Squassante L, Mitchell TR, Hale MD (2007) Sample size calculation for the Power Model for dose proportionality studies. Pharm Stat 6:35–41. https://doi.org/10.1002/pst.241
Smith BP (2004) Assessment of dose proportionality. In: Bonate P (ed) Pharmacokinetics in drug development: vol 1, clinical study design and analysis. AAPS Press, Arlington
Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST (2000) Confidence interval criteria for assessment of dose proportionality. Pharm Res 17:1278–1283
US FDA (2001) Guidance for industry: statistical approaches to establishing bioequivalence. Office of Training and Communications, Division of Communications Management, Maryland
US FDA (2014) Draft guideline for industry: bioavailability and bioequivalence studies submitted in NDAs or INDs – general considerations, Mar 2014
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this entry
Cite this entry
Eisenblaetter, T., Teichert, L., Burnette, R., Hutson, P. (2018). Dose Linearity and Proportionality. In: Hock, F., Gralinski, M. (eds) Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-56637-5_5-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56637-5_5-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56637-5
Online ISBN: 978-3-319-56637-5
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences